The DESTINY-Lung01 Trial demonstrated promising results for the use of trastuzumab deruxtecan (T-DXd) in treating patients with HER2-mutant non-small cell lung cancer (NSCLC). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.